Compass Therapeutics share price logo

Compass Therapeutics

NASDAQ: CMPX

Small Cap

$2.48

+0.09

(+3.77%)

as on

Compass Therapeutics Stock Performance

as on August 20, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $2.41
    $2.52
    downward going graph

    2.82%

    Downside

    1.61%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.61
    $6.88
    downward going graph

    35.08%

    Downside

    177.42%

    Upside

    downward going graph

Compass Therapeutics share price movements today

Previous Close
$2.39
Open
$2.42
Volume
4.1M
Market Cap
$405.2M
Day's Low - High
$2.41 - $2.52
52 Week Low - High
$1.61 - $6.88

Compass Therapeutics Historical Returns

1 Month Return
+ 9.76 %
3 Month Return
+ 20.97 %
1 Year Return
-24.24 %
3 Year Return
-5.46 %
5 Year Return
0 %

Compass Therapeutics Stock Fundamentals & Key Indicators

Check Compass Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$405.2M

EPS (TTM)

-0.415

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-5.45

Industry PE ratio

-7.283372093023256

PEG Ratio

-0.6187845889050707

EBITDA

-72.7M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-38.71%

Compass Therapeutics Stock Valuation

Track how Compass Therapeutics P/E has moved over time to understand its valuation trends.

Compass Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-13.49x)

December 31, 2022

Today (-12.79x)

December 31, 2025

Industry (-7.28x)

December 31, 2025

Highest (-2.43x)

December 31, 2021

LowHigh

Today’s Price to Earnings Ratio: -12.79x

Compass Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Compass Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$405.2MNA-5.450.00%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Compass Therapeutics Stock including INR - Dollar returns

The Compass Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Compass Therapeutics investment value today

Current value as on today

₹91,828

Returns

-₹8,172

(-8.17%)

Returns from Compass Therapeutics Stock

-₹16,498 (-16.5%)

Dollar Impact

₹8,326 (+8.33%)

Analyst Recommendation on Compass Therapeutics Stock

Based on 7 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 7 analysts, 100% of analysts recommend a 'BUY' rating for Compass Therapeutics. Average target price of $8.92

Compass Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Compass Therapeutics.

What analysts predicted

72.2%UPSIDE

Target Price

$8.92

Current Price

$2.48

Analyzed by

7 Analysts

Target

$8.92

Compass Therapeutics target price $8.92, a slight upside of 72.2% compared to current price of $2.48. According to 7 analysts rating.

Indian Investors' Interest in Compass Therapeutics Stock

Search interest for Compass Therapeutics Stock has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-14% versus previous 30 day period

Compass Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
0
-
-
-
-
-
-
-
-
Gross Profit
-
0
-
-
-
-
-
0
0
-
Operating Income
-12
-15
-12
-16
-17
-21
-15
-17
-20
-26
EBITDA
-10
-12
-10
-14
-16
-19
-14
-15
-17
-25
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-10
-13
-10
-15
-16
-19
-14
-15
-18
-25
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-10
-13
-10
-15
-16
-19
-14
-15
-18
-25
Net Profit Margin
0.00%
100.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Compass Therapeutics Annual Profit & Loss

All numbers in Millions USD

Mar 2019
Mar 2020
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
0
-
Gross Profit
-1
-
-
-
-
-
0
-1
Operating Income
-38
-34
-27
-81
-41
-50
-56
-72
EBITDA
-35
-31
-25
-80
-34
-40
-47
-65
Interest Expense
0
1
0
0
2
-
-
-
Depreciation
1
2
2
1
1
1
1
1
Income Before Tax
-38
-34
-29
-82
-39
-42
-49
-66
Income Tax Expense
0
0
0
-
-
-
-
-
Net Income
-38
-34
-29
-82
-39
-42
-49
-66
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
100.00%
0.00%

Compass Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-10
-13
-10
-15
-16
-19
-14
-15
-18
-25
Operating Cash Flow
-13
-10
-11
-9
-13
-11
-10
-13
-17
-13
Investing Cash Flow
-4
6
29
15
11
-6
-95
-3
38
-4
Financing Cash Flow
17
0
0
0
0
-
129
1
3
-3
Change in Cash
0
-4
17
6
-2
-18
23
-15
24
-22

Compass Therapeutics Annual Cash Flow

All numbers in Millions USD

Mar 2019
Mar 2020
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-38
-34
-29
-82
-39
-42
-49
-66
Operating Cash Flow
-33
-31
-26
-19
-34
-40
-44
-49
Investing Cash Flow
-2
0
0
-1
-151
26
46
-93
Financing Cash Flow
64
0
48
118
75
2
17
129
Change in Cash
28
-32
21
97
-109
-10
19
-12

Mutual Funds that own Compass Therapeutics Stock

Check out the Mutual Funds with significant holdings in Compass Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.277175%
5901798
Fidelity Concord Street Trust
0.859681%
1548183
Fidelity Salem Street Trust
0.790626%
1423822
VANGUARD SCOTTSDALE FUNDS
0.426488%
768054
ROYCE FUND
0.358793%
646144

Global Institutional Holdings in Compass Therapeutics

Funds
Holdings
SPDR
4.12%
Vanguard
3.97%
iShares
3.01%
James E. Flynn
2%
Stephen A. Schwarzman
1.03%

Insights on Compass Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, CMPX stock has moved up by 9.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 624.7% return, outperforming this stock by 620.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 493.6% return, outperforming this stock by 504.4%

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
OrganisationCompass Therapeutics
Headquarters80 Guest Street, Boston, MA, United States, 02135
IndustryBiotechnology
CEODr. Thomas J. Schuetz M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Compass Therapeutics

Name

Title

Dr. Thomas J. Schuetz M.D., Ph.D.

CEO & Vice Chairman

Mr. Barry Shin J.D., M.B.A.

Chief Financial Officer

Mr. Neil L. Lerner CPA

Senior VP & Chief Accounting Officer

Anna Gifford

Senior Manager of Communications & Chief of Staff

Ms. Karin Herrera B.A.

Senior VP & Head of Clinical Operations

Dr. James Kranz Ph.D.

VP and Head of Chemistry Manufacturing & Controls

Mr. Arjun Prasad M.B.A., M.P.H.

Chief Commercial Officer

Mr. Jonathan E. Anderman J.D.

Senior VP, General Counsel & Corporate Secretary

Mr. Bing Gong Ph.D.

Chief Scientific Officer

Dr. Cynthia A. Sirard M.D., Ph.D.

Chief Medical Officer

FAQs

What is Compass Therapeutics share price today?

Compass Therapeutics share price today is $2.48 as on at the close of the market. Compass Therapeutics share today touched a day high of $2.52 and a low of $2.41.

What is the 52 week high and 52 week low for Compass Therapeutics share?

Compass Therapeutics share touched a 52 week high of $6.88 on and a 52 week low of $1.61 on . Compass Therapeutics stock price today i.e. is closed at $2.48,which is 63.95% down from its 52 week high and 54.04% up from its 52 week low.

What is Compass Therapeutics's market capitalisation today?

Compass Therapeutics market capitalisation is $0.00T as on .

How to invest in Compass Therapeutics Stock (CMPX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Compass Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Compass Therapeutics Shares that will get you 0.6048 shares as per Compass Therapeutics share price of $2.48 per share as on August 20, 2026 at 8:46 am IST.

What is the minimum amount required to buy Compass Therapeutics Stock (CMPX) from India?

Indian investors can start investing in Compass Therapeutics (CMPX) shares with as little as ₹95.695 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.95 in Compass Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Compass Therapeutics share’s latest price of $2.48 as on August 20, 2026 at 8:46 am IST, you will get 4.0323 shares of Compass Therapeutics. Learn more about fractional shares .